Top 10 Publications
Top 10 Publications
Auto-Abs neutralizing type I IFNs underlying life-threatening viral diseases
1. P. Bastard et al., Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science (2020).
More than 15% of patients with life-threatening COVID-19 had auto-Abs neutralizing type I IFNs. This auto-immune phenocopy of the genetic deficiency, leads not only to severe COVID-19, but to a broader range of viral diseases (severe influenza, adverse reactions to yellow fever live attenuated vaccination, West Nile virus encephalitis and more).
2. P. Bastard et al., Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol (2021).
Study testing >34,000 individuals from the general population between the ages of 0-100 years old, finding that the prevalence of the auto-Abs against type I IFNs increased with age, especially in men.
3. P. Bastard et al. Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine. J Exp Med (2021).
Auto-Abs against type I IFNs can underlie severe reactions to live attenuated vaccines and arboviral diseases.
4. P. Bastard et al., Higher COVID-19 pneumonia risk associated with anti-IFN-a than with anti-IFN-w auto-Abs in children. J Exp Med (2024).
Children are at higher risk of COVID-19 when harboring auto-Abs to IFN-a
5. P. Bastard et al., Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs. Sci Immunol (2022).
I found that despite full vaccination scheme with 2 doses, adults with auto-Abs neutralizing type I IFNs can still be are at higher risk of COVID-19 pneumonia.
Monogenic causes underlying the production of auto-Abs against type I IFNs
6. Le Voyer T., (…) Bastard, P., Roifman, C. M., Landegren, N., Notarangelo, L. D., Anderson, M. S., Casanova, J. L., Puel, A. Autoantibodies against type I IFNs in humans with alternative NF-kappaB pathway deficiency. Nature (2023).
Discovery that NFKB2 deficient patient have devective AIRE in the thymus, underlysing AAN-I-IFNs.
Genetic defects underlying severe viral diseases
7. Zhang Q, Bastard P, Liu Z, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. (2020).
Initial discovery that inborn errors of immunity affecting the type I IFN pathway could lead to severe COVID-19. Including patients with complete IFNAR1 or IFNAR2 defects.
8. Chan, Y.H.*, Z. Liu*, P. Bastard* et al., Human TMEFF1 is a restriction factor for herpes simplex virus in the brain. Nature (2024). *: co-first authors. (> 50 co-authors).
I co-discovered that TMEFF1 functions as a crucial restriction factor, inhibiting viral entry into human cortical neurons via interacting with the HSV-1 receptor NECTIN-1 on the cell surface. It is the first cell-specific viral restriction factor whose defect leads to severe viral disease in Humans.
9. P. Bastard et al., A loss-of-function IFNAR1 allele in Polynesia underlies severe viral diseases in homozygotes. J Exp Med (2022).
A common loss-of-function allele leads to seevre viral disease in homozygocity in polynesia. Clinical implications are immediate, and local colleagues have lauched a nation-wide screening program.
10. P. Bastard et al., Herpes simplex encephalitis in a patient with a distinctive form of inherited IFNAR1 deficiency. J Clin Invest (2020). (> 50 co-authors).
Herpes simplex virus encephalitis (HSE) is the most frequent sporadic viral encephalitis in the Western world. I identified and then characterized in depth a patient who had suffered from HSE and harbored a large homozygous deletion in IFNAR1 (the receptor of type I IFNs). The cells from the patient were totally unresponsive to type I IFNs and highly susceptible to viruses. These findings indicate that CNS neuron-intrinsic immunity to viruses in the forebrain is controlled by type I IFNs.
Reviews
1. P. Bastard, Why do people die from COVID-19? Science (2022).
2. Bastard P, Gervais A, (…) Casanova JL, Human autoantibodies neutralizing type I IFNs: From 1981 to 2023. Immunol Rev (2024)
3. Bastard P, Zhang Q, Zhang SY, Jouanguy E, Casanova JL. Type I interferons and SARS-CoV-2: from cells to organisms. Curr Opin Immunol (2022)
4. Casanova JL, Peel J, Donadieu J, Neehus AL, Puel A, Bastard P. The ouroboros of autoimmunity. Nat Immunol (2024)